Sign In
Last checked at 
4 Nov 2025 07:00
Arecor Therapeutics plc("Arecor" or the "Company")
Arecor Enhances IP Coverage for AT278 and Oral Delivery Technology
Cambridge, UK, 4 November 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, provides an update on the broadening of its IP position.
AT278 IP
Arecor has strengthened its patent protection for its lead programme, AT278, the only ultra-concentrated and ultra-rapid acting insulin in development with the potential to enable longer-wear for existing automated insulin delivery (AID) systems and their future miniaturisation. A US patent has been granted to protect key formulations and uses of AT278. In addition, another patent with respect to AT278 intellectual property has been approved for grant by the European Patent Office, providing further patent protection in Europe.
Oral peptide delivery IP
Arecor has also filed a patent application with the European Patent office, claiming novel compositions to improve the oral bioavailability of complex peptides. Novel peptide therapeutics are proving to be highly effective to treat chronic conditions such as obesity, diabetes and other cardiometabolic diseases, and there is growing evidence that oral delivery improves patient compliance and adherence.
Poor oral bioavailability remains a major barrier to developing convenient oral peptide therapies. Arecor is addressing this challenge through novel therapeutic formulations designed to improve the oral bioavailability of peptides. The new patent application protects the key formulation design space discovered in initial investigations with additional patent applications expected to follow as R&D progresses.
Dr Jan Jezek, CSO of Arecor said:
"As an innovative company developing novel therapies and platforms, protecting our IP is essential to our business. We are continuously updating our IP protection to secure its value and we are pleased to have received additional patent protection in Europe and the US for our ultra-concentrated ultra-rapid acting insulin, AT278. We have also filed our first patent application in the oral peptide delivery space, which is an important moment for us, with more to come as our R&D programme progresses."
The new patents add to a robust global intellectual property portfolio of the Company protecting AT278 and the Arestat® technology, and follow a number of additional patents already granted in major territories.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc Dr Sarah Howell, Chief Executive OfficerDavid Ellam, Chief Financial Officer | +44 (0) 1223 426060 info@arecor.com |
|
|
Singer Capital Markets Advisory LLP (NOMAD and Broker) | +44 (0) 20 7496 3000 |
Phil Davies, Sam Butcher |
|
|
|
Vigo Consulting Melanie Toyne-Sewell, Rozi Morris | +44 (0) 20 7390 0230 arecor@vigoconsulting.com |
|
Notes to Editors
About Arecor
Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases. The Company is applying its proprietary technology platform, Arestat®, to develop a portfolio of proprietary products, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin. Arecor is also developing a novel oral delivery platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com.
Arecor® and Arestat® are registered trademarks of Arecor Limited.
Follow the stocks
